Online inquiry

IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6077MR)

This product GTTS-WQ6077MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CCL2 gene. The antibody can be applied in Pulmonary Fibrosis research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002982.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6347
UniProt ID P13500
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ6077MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9847MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA JTX-2011
GTTS-WQ2858MR IVTScrip™ mRNA-Anti-ICOS, AMG-570(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG-570
GTTS-WQ3288MR IVTScrip™ mRNA-Anti-alpha toxin&<br />lukE, ASN-1(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ASN-1
GTTS-WQ1359MR IVTScrip™ mRNA-Anti-IL12B, ABT-874(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-874
GTTS-WQ11694MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MHAB5553A
GTTS-WQ3127MR IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA APN311
GTTS-WQ3179MR IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ARENEGYR
GTTS-WQ10233MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LFB-R593
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW